Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | BGB-A3055 |
| Trade Name | |
| Synonyms | BGBA3055|BGB A3055 |
| Drug Descriptions |
BGB-A3055 is a monoclonal antibody that targets CCR8 expressed on regulatory T-cells and inhibits downstream signaling, potentially leading to enhanced antitumor immune response (NCI Drug Dictionary). |
| DrugClasses | CCR8 Antibody 13 |
| CAS Registry Number | NA |
| NCIT ID | C203903 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| BGB-A3055 | BGB-A3055 | 0 | 1 |
| BGB-A3055 + Tislelizumab | BGB-A3055 Tislelizumab | 0 | 1 |